Acquisition Completed Sponsor buyer

Chiesi Group acquisition of KalVista Pharmaceuticals

US$1.9bn equity value

Announced 29 Apr 2026 · NASDAQ: KALV · US$27.00 cash per share · 36% premium

Advisers

KalVista Pharmaceuticals

Target

Financial adviser
Fairness opinion

Parent

Acquirer

Financial adviser
Legal adviser
Target
KalVista Pharmaceuticals
Acquirer
Parent (Chiesi Group)
Sponsor
Chiesi Group
Target based in
United States
Buyer based in
Italy
Completed
11 Jun 2026
Sector
Pharma
Tags
Pharma, Biotech, Rare Disease

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.